Skip to content
10-Q

Quarterly Report

Moleculin Biotech, Inc. MBRX

0001437749-26-017034

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 5.34M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.11M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.56M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $10.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $8.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $15.18M
Stockholders Equity Q1 2026 · Dec 31, 2025 $15.01M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $13.79M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 $11.21M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.96M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.85M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.18M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.12M
Current Assets Q1 2026 · Mar 31, 2026 $10.96M
Current Assets Q1 2026 · Dec 31, 2025 $9.69M
Total Assets Q1 2026 · Mar 31, 2026 $23.36M
Total Assets Q1 2026 · Dec 31, 2025 $22.13M
Eps Basic Q1 2026 · Mar 31, 2026 −$3.54
Eps Basic restated Q1 2026 · Mar 31, 2025 −$15.80
Sga Expense Q1 2026 · Mar 31, 2026 $2.49M
Sga Expense Q1 2026 · Mar 31, 2025 $2.48M
Rd Expense Q1 2026 · Mar 31, 2026 $5.38M
Rd Expense Q1 2026 · Mar 31, 2025 $3.44M
Net Income Q1 2026 · Mar 31, 2026 −$12.85M
Net Income restated Q1 2026 · Mar 31, 2025 −$5.9M
Operating Income Q1 2026 · Mar 31, 2026 −$7.87M
Operating Income Q1 2026 · Mar 31, 2025 −$5.94M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0